Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | enGene CMO Dr. Raj Pruthi to step down mid-June | 1 | Investing.com | ||
Mi | enGene CMO Dr. Raj Pruthi verlässt Unternehmen Mitte Juni | - | Investing.com Deutsch | ||
ENGENE HOLDINGS Aktie jetzt für 0€ handeln | |||||
Mi | enGene Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
28.05. | enGene appoints new Chief Global Commercialization Officer | 1 | Investing.com | ||
29.04. | Citizens JMP reiterates Engene stock with $18 target | 1 | Investing.com | ||
11.03. | Engene stock holds Buy rating, $25 target from H.C. Wainwright | 1 | Investing.com | ||
10.03. | enGene Holdings GAAP EPS of $0.48 | 2 | Seeking Alpha | ||
10.03. | enGene Holdings Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
10.03. | enGene Holdings Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
10.03. | enGene Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
20.02. | enGene Holdings Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
18.02. | Piper Sandler sets $26 target on Engene shares with Overweight rating | 3 | Investing.com | ||
19.12.24 | enGene Holdings GAAP EPS of -$1.46 misses by $0.03 | 1 | Seeking Alpha | ||
19.12.24 | enGene Reports Full Year 2024 Financial Results and Provides a Business Update | 119 | Business Wire | BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene... ► Artikel lesen | |
19.12.24 | enGene Holdings Inc. - 10-K, Annual Report | - | SEC Filings | ||
19.12.24 | enGene Holdings Inc. - 8-K, Current Report | - | SEC Filings | ||
10.09.24 | enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update | 154 | Business Wire | BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene... ► Artikel lesen | |
14.06.24 | enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update | 318 | Business Wire | BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 95,35 | +0,05 % | BioNTech SE: BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt | BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen Behandlungsstandard... ► Artikel lesen | |
CUREVAC | 3,830 | -0,83 % | Kauf-Alarm bei CureVac: Insider decken sich massenhaft mit Aktien ein - Das müssen Sie jetzt beachten! | ||
AMGEN | 254,90 | +0,08 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
NOVAVAX | 6,520 | -0,20 % | Aktien New York: Rücksetzer nach US-Bonitätsabstufung verpufft | NEW YORK (dpa-AFX) - Die Abstufung der US-Kreditwürdigkeit durch Moody?s hat die Anleger in New York am Montag nicht lange beeindruckt. Benoit Anne, Anleiheexperte bei MFS Investment Management, verwies... ► Artikel lesen | |
BIOGEN | 116,70 | -0,09 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | ||
MAINZ BIOMED | 2,775 | -100,00 % | MAINZ BIOMED N.V. - 6-K, Report of foreign issuer | ||
VIKING THERAPEUTICS | 24,220 | -0,78 % | Viking Therapeutics auf Jefferies-Konferenz: Vielversprechendes Abnehm-Medikament | ||
INTELLIA THERAPEUTICS | 7,146 | +0,37 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 9,668 | -0,17 % | BioCryst Pharmaceuticals, Inc.: BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries | RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland... ► Artikel lesen | |
TEMPUS AI | 54,74 | +0,51 % | XFRA NEW INSTRUMENTS AVAILABLE ON 03.06.2025 | The following instruments on XETRA do have their first trading 03.06.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 03.06.2025
Aktien
1 US88023B1035 Tempus AI Inc.
2 KYG9482E1180... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 38,180 | +1,17 % | FDA Grants Platform Technology Status To Sarepta's RAAVrh74 Vector | WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT), Wednesday announced that the FDA has designated its rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 for limb-girdle... ► Artikel lesen | |
CARDIOL THERAPEUTICS | 1,218 | -1,30 % | H.C. Wainwright initiates Cardiol Therapeutics stock with buy rating | ||
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,000 | +1,26 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 8-K, Current Report | ||
EXELIXIS | 37,400 | -0,93 % | BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution | ||
VAXART | 0,364 | +2,42 % | Vaxart, Inc.: Vaxart Announces Adjournment of Annual Meeting of Stockholders |